Cargando…

40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA

BACKGROUND: Neuroinflammation is attractive as a candidate mechanism contributing to schizophrenia neuropathology. In ~40% of people with schizophrenia, pro-inflammatory cytokines are elevated in post mortem prefrontal cortex and in peripheral blood of living patients. Dopamine dysregulation contrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Purves-Tyson, Tertia, Rothmond, Debora, Weickert, Cynthia Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888622/
http://dx.doi.org/10.1093/schbul/sby014.164
_version_ 1783312565849292800
author Purves-Tyson, Tertia
Rothmond, Debora
Weickert, Cynthia Shannon
author_facet Purves-Tyson, Tertia
Rothmond, Debora
Weickert, Cynthia Shannon
author_sort Purves-Tyson, Tertia
collection PubMed
description BACKGROUND: Neuroinflammation is attractive as a candidate mechanism contributing to schizophrenia neuropathology. In ~40% of people with schizophrenia, pro-inflammatory cytokines are elevated in post mortem prefrontal cortex and in peripheral blood of living patients. Dopamine dysregulation contributes to cognitive deficits and psychosis and cytokines can increase dopamine production, yet post mortem midbrain cytokine transcripts have not been examined. We hypothesised that gene expression of inflammatory markers will be elevated in the midbrain of a subset of people that suffered with schizophrenia during their lives. METHODS: Pro-inflammatory cytokine mRNAs for interleukin (IL) 1β, IL6, IL6 signal transducer (IL6ST), IL8, 1L18, tumor necrosis factor (TNF) α, SERPINA3, and the microglia marker, allograft inflammatory factor 1 (AIF1), were examined by qPCR in the midbrain from 28 schizophrenia cases and 29 healthy controls. All patients were on antipsychotics at time of death and antipsychotic medication was converted to chlorpromazine (CPZ) equivalents. Inflammatory subgroups were defined using two-step cluster analysis of cytokine mRNAs on the entire cohort. Chi-squared was used to test if the number of individuals in the inflammatory groups differed on the basis of diagnosis. Student’s t-tests or ANCOVA were used to detect diagnostic differences and differences between inflammatory/diagnosis subgroups. Student’s t-tests were used to compare CPZ equivalent doses in the low and high inflammation schizophrenia groups. RESULTS: SERPINA3, IL1β, IL6 mRNAs were increased by more than 150% and IL6ST mRNA by 17% in the midbrain from schizophrenia patients compared to controls (F>4.0, p<0.0001–0.05), whilst IL8, IL18 and AIF1 mRNAs were unchanged (p>0.05). Cluster analysis revealed 13 individuals as high inflammation and 44 as low inflammation. All 13 individuals in the high inflammatory group were schizophrenia cases and the remaining 15 schizophrenia cases and all the control cases were low inflammation (χ2=57.0, P<0.0001, N=57). SERPINA3, IL6, IL1β and TNFα mRNAs were all increased in the high inflammation/schizophrenia compared to control and low inflammation/schizophrenia groups (p<0.002–0.05). AIF mRNA was not changed by diagnosis, but was increased in the high inflammation/schizophrenia compared to the low inflammation/schizophrenia group (p=0.015). The schizophrenia/high inflammation group received higher lifetime, daily and last CPZ equivalent doses (t(20–26)<-2.7, p<0.05) compared to the schizophrenia/low inflammation group. DISCUSSION: Inflammatory markers were elevated in the midbrain in ~50% of schizophrenia cases, whilst no controls were classified as high inflammation. This data suggests that increases in pro-inflammatory cytokines extend to midbrain regions and may contribute to the neuropathology of the disorder by contributing to dopamine dysregulation. PET studies relate increased microglia activity to at-risk symptom severity in medication naïve people at ultra high risk for schizophrenia, we suggest that the higher dose of antipsychotics in the high inflammation group along with increased microglial marker may indicate that these patients were sicker and thus, required more medication, rather than antipsychotics increasing inflammatory markers. In conclusion, increased cytokine transcripts indicate a neuroinflammatory process in the midbrain in some people with schizophrenia. Future post mortem studies will explore whether previously identified changes in dopamine-related transcripts in the midbrain in schizophrenia are altered according to inflammatory state.
format Online
Article
Text
id pubmed-5888622
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58886222018-04-11 40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA Purves-Tyson, Tertia Rothmond, Debora Weickert, Cynthia Shannon Schizophr Bull Abstracts BACKGROUND: Neuroinflammation is attractive as a candidate mechanism contributing to schizophrenia neuropathology. In ~40% of people with schizophrenia, pro-inflammatory cytokines are elevated in post mortem prefrontal cortex and in peripheral blood of living patients. Dopamine dysregulation contributes to cognitive deficits and psychosis and cytokines can increase dopamine production, yet post mortem midbrain cytokine transcripts have not been examined. We hypothesised that gene expression of inflammatory markers will be elevated in the midbrain of a subset of people that suffered with schizophrenia during their lives. METHODS: Pro-inflammatory cytokine mRNAs for interleukin (IL) 1β, IL6, IL6 signal transducer (IL6ST), IL8, 1L18, tumor necrosis factor (TNF) α, SERPINA3, and the microglia marker, allograft inflammatory factor 1 (AIF1), were examined by qPCR in the midbrain from 28 schizophrenia cases and 29 healthy controls. All patients were on antipsychotics at time of death and antipsychotic medication was converted to chlorpromazine (CPZ) equivalents. Inflammatory subgroups were defined using two-step cluster analysis of cytokine mRNAs on the entire cohort. Chi-squared was used to test if the number of individuals in the inflammatory groups differed on the basis of diagnosis. Student’s t-tests or ANCOVA were used to detect diagnostic differences and differences between inflammatory/diagnosis subgroups. Student’s t-tests were used to compare CPZ equivalent doses in the low and high inflammation schizophrenia groups. RESULTS: SERPINA3, IL1β, IL6 mRNAs were increased by more than 150% and IL6ST mRNA by 17% in the midbrain from schizophrenia patients compared to controls (F>4.0, p<0.0001–0.05), whilst IL8, IL18 and AIF1 mRNAs were unchanged (p>0.05). Cluster analysis revealed 13 individuals as high inflammation and 44 as low inflammation. All 13 individuals in the high inflammatory group were schizophrenia cases and the remaining 15 schizophrenia cases and all the control cases were low inflammation (χ2=57.0, P<0.0001, N=57). SERPINA3, IL6, IL1β and TNFα mRNAs were all increased in the high inflammation/schizophrenia compared to control and low inflammation/schizophrenia groups (p<0.002–0.05). AIF mRNA was not changed by diagnosis, but was increased in the high inflammation/schizophrenia compared to the low inflammation/schizophrenia group (p=0.015). The schizophrenia/high inflammation group received higher lifetime, daily and last CPZ equivalent doses (t(20–26)<-2.7, p<0.05) compared to the schizophrenia/low inflammation group. DISCUSSION: Inflammatory markers were elevated in the midbrain in ~50% of schizophrenia cases, whilst no controls were classified as high inflammation. This data suggests that increases in pro-inflammatory cytokines extend to midbrain regions and may contribute to the neuropathology of the disorder by contributing to dopamine dysregulation. PET studies relate increased microglia activity to at-risk symptom severity in medication naïve people at ultra high risk for schizophrenia, we suggest that the higher dose of antipsychotics in the high inflammation group along with increased microglial marker may indicate that these patients were sicker and thus, required more medication, rather than antipsychotics increasing inflammatory markers. In conclusion, increased cytokine transcripts indicate a neuroinflammatory process in the midbrain in some people with schizophrenia. Future post mortem studies will explore whether previously identified changes in dopamine-related transcripts in the midbrain in schizophrenia are altered according to inflammatory state. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5888622/ http://dx.doi.org/10.1093/schbul/sby014.164 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Purves-Tyson, Tertia
Rothmond, Debora
Weickert, Cynthia Shannon
40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
title 40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
title_full 40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
title_fullStr 40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
title_full_unstemmed 40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
title_short 40.1 INFLAMMATORY CYTOKINES ARE ELEVATED IN THE MIDBRAIN IN SCHIZOPHRENIA
title_sort 40.1 inflammatory cytokines are elevated in the midbrain in schizophrenia
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888622/
http://dx.doi.org/10.1093/schbul/sby014.164
work_keys_str_mv AT purvestysontertia 401inflammatorycytokinesareelevatedinthemidbraininschizophrenia
AT rothmonddebora 401inflammatorycytokinesareelevatedinthemidbraininschizophrenia
AT weickertcynthiashannon 401inflammatorycytokinesareelevatedinthemidbraininschizophrenia